AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 380256 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg, 1-2 tablets as needed, max 5 tablets daily)
Number of subjects: 97
Study 380256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 380256 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 97
Study 29999203 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy with real-time visual feedback
Number of subjects: 29
Study 29999203 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy without real-time visual feedback
Number of subjects: 29
Study 28027276 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses (MF, +2.50D center distance add)
Number of subjects: 16
Study 28027276 — intervention group
Group type: COMPARATOR
Intervention: Single vision contact lenses (SV)
Number of subjects: 16
Study 25579161 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia (E group, n=26)
Number of subjects: 53
Study 25579161 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (G group, n=27)
Number of subjects: 53
Study 25579161 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia (E group)
Number of subjects: 53
Study 25579161 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (G group)
Number of subjects: 53
Study 23528731 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory mixture followed by the same olfactory mixture
Number of subjects: 0
Study 23528731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure odor followed by the same pure odor
Number of subjects: 0
Study 21223565 — intervention group
Group type: EXPERIMENTAL
Intervention: Completing a questionnaire based on the Theory of Planned Behavior (TPB) regarding leisure-time physical activity.
Number of subjects: 452
Study 21223565 — intervention group
Group type: COMPARATOR
Intervention: Completing a questionnaire on fruit and vegetable consumption (control condition).
Number of subjects: 452
Study 19552840 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple negative breast cancer patients
Number of subjects: 690
Study 17377104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% ropivacaine
Number of subjects: 104
Study 17377104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% levobupivacaine
Number of subjects: 104
Study 17377104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine
Number of subjects: 104
Study 17377104 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine vs Bupivacaine
Number of subjects: 104
Study 17377104 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine vs Levobupivacaine
Number of subjects: 104
Study 17377104 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine vs Bupivacaine
Number of subjects: 104
Study 16036036 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human BNP (nesiritide) as an intravenous treatment for acute decompensated HF
Number of subjects: 0
Study 16036036 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP and NT-proBNP blood measurements
Number of subjects: 0
Study 11552555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical Issues Scale (EIS)
Number of subjects: 2090
Study 9972082 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma transferrin
Number of subjects: 15
Study 9972082 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibronectin
Number of subjects: 15
Study 9972082 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma albumin
Number of subjects: 15
Study 9972082 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anaemia
Number of subjects: 15
Study 9972082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibronectin assay
Number of subjects: 15
Study 7846948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.125 mg three times daily up to 0.25 mg twice daily)
Number of subjects: 45
Study 7846948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.125 mg twice daily) and quinidine hydrogen sulphate (750‐1000 mg daily)
Number of subjects: 45
Study 7846948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.125 mg three times daily) and flecainide (200‐300 mg daily)
Number of subjects: 45
Study 3132352 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Mack‐Retard 20
Number of subjects: 45
Study 3132352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1103007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrasanone (Carudol)
Number of subjects: 719
Study 31286734 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint thread-embedding therapy (operated once every 30 days, total of 2 treatments)
Number of subjects: 88
Study 31286734 — intervention group
Group type: COMPARATOR
Intervention: Topical artificial tears eye drops (4 to 6 times a day, one drop each time, for 8 weeks)
Number of subjects: 88
Study 27702701 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal vaginal cuff closure
Number of subjects: 43
Study 27702701 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical vaginal cuff closure
Number of subjects: 43
Study 27702701 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Horizontal and Vertical)
Number of subjects: 43
Study 25754126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinospora cordifolia aqueous extract (TCE)
Number of subjects: 0
Study 25754126 — intervention group
Group type: COMPARATOR
Intervention: Control group (apparently healthy subjects)
Number of subjects: 0
Study 23874638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-familiarity logos
Number of subjects: 0
Study 23874638 — intervention group
Group type: COMPARATOR
Intervention: Middle-familiarity logos
Number of subjects: 0
Study 23874638 — intervention group
Group type: COMPARATOR
Intervention: Low-familiarity logos
Number of subjects: 0
Study 23874638 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic association in high-familiarity brands
Number of subjects: 0
Study 23874638 — intervention group
Group type: COMPARATOR
Intervention: Semantic association in low-familiarity brands
Number of subjects: 0
Study 21444600 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-centered physical-activity program
Number of subjects: 165
Study 21444600 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-centered dietary-modification program
Number of subjects: 165
Study 21444600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both child-centered physical-activity program and parent-centered dietary-modification program
Number of subjects: 165
Study 21444600 — intervention group
Group type: COMPARATOR
Intervention: Activity-only group
Number of subjects: 165
Study 21444600 — intervention group
Group type: COMPARATOR
Intervention: Diet-only group
Number of subjects: 165
Study 21444600 — intervention group
Group type: COMPARATOR
Intervention: Activity + diet group
Number of subjects: 165
Study 19002533 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop training (rater error training, performance dimension training, behavioral observation training, frame of reference training)
Number of subjects: 52
Study 19002533 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop training
Number of subjects: 52
Study 19002533 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (no intervention until after posttest)
Number of subjects: 52
Study 19002533 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop group
Number of subjects: 52
Study 19002533 — intervention group
Group type: COMPARATOR
Intervention: Workshop group and Delayed group
Number of subjects: 52
Study 16753012 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg daily
Number of subjects: 10739
Study 15546651 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture (SPEC)
Number of subjects: 61
Study 15546651 — intervention group
Group type: COMPARATOR
Intervention: Active control acupuncture (NSPEC)
Number of subjects: 61
Study 15546651 — intervention group
Group type: COMPARATOR
Intervention: Massage (MSSG)
Number of subjects: 61
Study 15546651 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEC
Number of subjects: 61
Study 15546651 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 61
Study 11139910 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular (RV) pacing
Number of subjects: 13
Study 11139910 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) pacing
Number of subjects: 13
Study 11139910 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BV) pacing
Number of subjects: 13
Study 9491191 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and phosphorus-enriched formula
Number of subjects: 36
Study 9491191 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 36
Study 8375536 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF‐ET
Number of subjects: 59
Study 8375536 — intervention group
Group type: COMPARATOR
Intervention: ZIFT
Number of subjects: 59
Study 3530139 — intervention group
Group type: EXPERIMENTAL
Intervention: CMitF (mitoxantrone, cyclophosphamide, and 5‐fluorouracil)
Number of subjects: 46
Study 3530139 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, adriamycin, and 5‐fluorouracil)
Number of subjects: 46
Study 3530139 — intervention group
Group type: EXPERIMENTAL
Intervention: CMitF
Number of subjects: 46
Study 3530139 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 46
Study 3530139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 29377065 — intervention group
Group type: COMPARATOR
Intervention: simple CHO drink
Number of subjects: 12
Study 29377065 — intervention group
Group type: EXPERIMENTAL
Intervention: simple CHO + whey protein drink (CHO + W)
Number of subjects: 12
Study 26639957 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab 0.5 mg/kg in carriers
Number of subjects: 0
Study 26639957 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab 1.0 mg/kg in noncarriers
Number of subjects: 0
Study 26639957 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab 0.5 mg/kg in noncarriers
Number of subjects: 0
Study 26639957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23872837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit-flavoured jelly containing 4 g of agar crystals
Number of subjects: 11
Study 23872837 — intervention group
Group type: COMPARATOR
Intervention: Fruit-flavoured drink (liquid)
Number of subjects: 11
Study 22365615 — intervention group
Group type: EXPERIMENTAL
Intervention: AWBAT-D™
Number of subjects: 14
Study 22365615 — intervention group
Group type: COMPARATOR
Intervention: Duoderm(®)
Number of subjects: 14
Study 20002369 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg of self‐administered vaginal misoprostol
Number of subjects: 67
Study 20002369 — intervention group
Group type: COMPARATOR
Intervention: Self‐administered vaginal placebo
Number of subjects: 67
Study 19025528 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil in ropivacaine (0.015 mcg/kg/ml sufentanil in 1.5 mg/ml ropivacaine, infused at 2 ml/h)
Number of subjects: 64
Study 19025528 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl in ropivacaine (0.1 mcg/kg/ml fentanyl in 1.5 mg/ml ropivacaine, infused at 2 ml/h)
Number of subjects: 64
Study 19025528 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil in ropivacaine
Number of subjects: 64
Study 19025528 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl in ropivacaine
Number of subjects: 64
Study 16308017 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery with preoperative cerebral ischemic injury
Number of subjects: 120
Study 16308017 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery with preoperative cerebral ischemic injury
Number of subjects: 120
Study 16308017 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cardiopulmonary bypass
Number of subjects: 120
Study 16308017 — intervention group
Group type: EXPERIMENTAL
Intervention: No independent effects found from baseline magnetic resonance imaging or new cerebral lesions
Number of subjects: 120
Study 12860494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg administered at -5 or -10 minutes relative to food
Number of subjects: 12
Study 12860494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg administered at -30 or -10 minutes
Number of subjects: 12
Study 12860494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10371365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampatrilat (50 to 100 mg daily)
Number of subjects: 58
Study 10371365 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10 to 20 mg daily)
Number of subjects: 58
Study 8904562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Ibu; 1,200 mg/day)
Number of subjects: 8
Study 8904562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1990938 — intervention group
Group type: EXPERIMENTAL
Intervention: M6 regimen (6 months of treatment with streptomycin, isoniazid, rifampin, and pyrazinamide)
Number of subjects: 240
Study 1990938 — intervention group
Group type: EXPERIMENTAL
Intervention: M8 regimen (8 months of treatment with streptomycin, isoniazid, rifampin, and pyrazinamide)
Number of subjects: 240
Study 1990938 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 240
Study 6523889 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy (M)
Number of subjects: 241
Study 6523889 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection (R)
Number of subjects: 241
Study 6523889 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (B) and chemoimmunotherapy (C)
Number of subjects: 241
Study 6523889 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (A)
Number of subjects: 241
Study 6523889 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast resection (non-randomized patients)
Number of subjects: 241
Study 30994287 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-time application, each time 750 mL per plant (F1)
Number of subjects: 0
Study 30994287 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-time application, each time 500 mL per plant (F2)
Number of subjects: 0
Study 30994287 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-time application, each time 375 mL per plant (F3)
Number of subjects: 0
Study 30994287 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating by 120% daily evapotranspiration (ET) before fruit enlargement, by 140%ET after fruit enlargement (W1)
Number of subjects: 0
Study 30994287 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating by 140%ET before fruit enlargement, by 160%ET after fruit enlargement (W2)
Number of subjects: 0
Study 30994287 — intervention group
Group type: EXPERIMENTAL
Intervention: F3W1 treatment (16-time application with 120% ET before and 140% ET after)
Number of subjects: 0
Study 30134291 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-containing ART
Number of subjects: 59
Study 30134291 — intervention group
Group type: COMPARATOR
Intervention: Viral load suppression to less than 50 copies/ml
Number of subjects: 59
Study 30134291 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 100 CD4 cells/μl on ART
Number of subjects: 59
Study 30134291 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF regimens
Number of subjects: 59
Study 30134291 — intervention group
Group type: COMPARATOR
Intervention: Non-TDF regimens
Number of subjects: 59
Study 27018361 — intervention group
Group type: EXPERIMENTAL
Intervention: AF Exercise Program (AFEP) enhanced with the '10 Keys'™ to Healthy Aging, delivered in 20 sessions over 10 weeks by community health workers.
Number of subjects: 0
Study 25176628 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with anesthesiologist assistance
Number of subjects: 204
Study 25176628 — intervention group
Group type: COMPARATOR
Intervention: Midazolam administered by cardiologist only
Number of subjects: 204
Study 22579647 — intervention group
Group type: EXPERIMENTAL
Intervention: WMFT mean rate of performance
Number of subjects: 32
Study 22579647 — intervention group
Group type: EXPERIMENTAL
Intervention: WMFT median performance times
Number of subjects: 32
Study 19947260 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication acupoint sticking therapy (using cakes made of grinding pepper, brassica alba seeds, asarum, mixed with ginger oil and ginger juice)
Number of subjects: 188
Study 19947260 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (using cakes made of powder of red rice, black rice, maize mixed with small amount of ginger juice)
Number of subjects: 188
Study 17936213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study 17936213 — intervention group
Group type: COMPARATOR
Intervention: Best available treatments
Number of subjects: 0
Study 15199394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy with a single 10-Gy treatment using 9-MeV electrons
Number of subjects: 58
Study 15199394 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic radiotherapy (control group)
Number of subjects: 58
Study 12038716 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient communication training (high, medium, or low intensive)
Number of subjects: 16
Study 12038716 — intervention group
Group type: COMPARATOR
Intervention: Pre-visit training
Number of subjects: 16
Study 12038716 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training
Number of subjects: 16
Study 9585392 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 9585392 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 9585392 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 9585392 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEIs)
Number of subjects: 0
Study 9585392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 0
Study 7712435 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (25 Gy during 5 to 7 days before surgery)
Number of subjects: 849
Study 7712435 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 849
Study 7712435 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 849
Study 2752557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg s.l.)
Number of subjects: 23
Study 2752557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (0.37 +/- 0.03 microgram/kg/min i.v.)
Number of subjects: 23
Study 2752557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sublingual)
Number of subjects: 23
Study 50181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean blood alcohol content of 90 mg%)
Number of subjects: 0
Study 50181 — intervention group
Group type: COMPARATOR
Intervention: Visual discrimination task (counting flashes and discriminating double flashes)
Number of subjects: 0
Study 50181 — intervention group
Group type: COMPARATOR
Intervention: Control and placebo conditions
Number of subjects: 0
Study 30295400 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (30 mg, subcutaneous, four-times daily) with naloxone (0.4 mg, IM) challenge
Number of subjects: 89
Study 30295400 — intervention group
Group type: COMPARATOR
Intervention: Clonidine, tramadol-ER, and buprenorphine (RCT medications)
Number of subjects: 89
Study 30523724 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative enteral nutrition
Number of subjects: 265
Study 30523724 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 265
Study 28257335 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin decrease of more than 80% from baseline to day 4
Number of subjects: 858
Study 28257335 — intervention group
Group type: COMPARATOR
Intervention: No procalcitonin decrease of more than 80% from baseline to day 4
Number of subjects: 858
Study 26159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention with guided chat counseling
Number of subjects: 0
Study 26159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention without chat counseling
Number of subjects: 0
Study 26159624 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported urinary incontinence
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress incontinence
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed incontinence
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge incontinence
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity index of urinary incontinence
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of protection for incontinence
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with a physician about symptoms
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index (BMI) ≥ 25 kg/m(2)
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic urinary tract infections
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 1307
Study 23096531 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hysterectomy or uterine leiomyomata
Number of subjects: 1307
Study 21737560 — intervention group
Group type: EXPERIMENTAL
Intervention: Small airway deposition of dornase alfa
Number of subjects: 49
Study 21737560 — intervention group
Group type: COMPARATOR
Intervention: Large airway deposition of dornase alfa
Number of subjects: 49
Study 18421187 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (group A, 22 patients)
Number of subjects: 32
Study 18421187 — intervention group
Group type: COMPARATOR
Intervention: Control (group B, 10 patients)
Number of subjects: 32
Study 17326486 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state cycling test at 75% of VO2 max for 30 minutes
Number of subjects: 20